Literature DB >> 24966608

Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.

Kouichi Miura1, Hirohide Ohnishi1.   

Abstract

Emerging data have shown a close association between compositional changes in gut microbiota and the development of nonalcoholic fatty liver disease (NAFLD). The change in gut microbiota may alter nutritional absorption and storage. In addition, gut microbiota are a source of Toll-like receptor (TLR) ligands, and their compositional change can also increase the amount of TLR ligands delivered to the liver. TLR ligands can stimulate liver cells to produce proinflammatory cytokines. Therefore, the gut-liver axis has attracted much interest, particularly regarding the pathogenesis of NAFLD. The abundance of the major gut microbiota, including Firmicutes and Bacteroidetes, has been considered a potential underlying mechanism of obesity and NAFLD, but the role of these microbiota in NAFLD remains unknown. Several reports have demonstrated that certain gut microbiota are associated with the development of obesity and NAFLD. For instance, a decrease in Akkermansia muciniphila causes a thinner intestinal mucus layer and promotes gut permeability, which allows the leakage of bacterial components. Interventions to increase Akkermansia muciniphila improve the metabolic parameters in obesity and NAFLD. In children, the levels of Escherichia were significantly increased in nonalcoholic steatohepatitis (NASH) compared with those in obese control. Escherichia can produce ethanol, which promotes gut permeability. Thus, normalization of gut microbiota using probiotics or prebiotics is a promising treatment option for NAFLD. In addition, TLR signaling in the liver is activated, and its downstream molecules, such as proinflammatory cytokines, are increased in NAFLD. To data, TLR2, TLR4, TLR5, and TLR9 have been shown to be associated with the pathogenesis of NAFLD. Therefore, gut microbiota and TLRs are targets for NAFLD treatment.

Entities:  

Keywords:  Gut microbiota; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Prebiotics; Probiotics; Toll-like receptor

Mesh:

Substances:

Year:  2014        PMID: 24966608      PMCID: PMC4064083          DOI: 10.3748/wjg.v20.i23.7381

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  114 in total

Review 1.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

2.  Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4.

Authors:  Gyongyi Szabo; Arumugam Velayudham; Laszlo Romics; Pranoti Mandrekar
Journal:  Alcohol Clin Exp Res       Date:  2005-11       Impact factor: 3.455

3.  Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women.

Authors:  A Santacruz; M C Collado; L García-Valdés; M T Segura; J A Martín-Lagos; T Anjos; M Martí-Romero; R M Lopez; J Florido; C Campoy; Y Sanz
Journal:  Br J Nutr       Date:  2010-03-08       Impact factor: 3.718

4.  Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease?

Authors:  Lorenza Conterno; Francesca Fava; Roberto Viola; Kieran M Tuohy
Journal:  Genes Nutr       Date:  2011-05-11       Impact factor: 5.523

5.  Inflammasome is a central player in the induction of obesity and insulin resistance.

Authors:  Rinke Stienstra; Janna A van Diepen; Cees J Tack; Md Hasan Zaki; Frank L van de Veerdonk; Deshani Perera; Geoffrey A Neale; Guido J Hooiveld; Anneke Hijmans; Irene Vroegrijk; Sjoerd van den Berg; Johannes Romijn; Patrick C N Rensen; Leo A B Joosten; Mihai G Netea; Thirumala-Devi Kanneganti
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-29       Impact factor: 11.205

6.  A single nucleotide polymorphism of Toll-like receptor 4 identifies the risk of developing graft failure after liver transplantation.

Authors:  Navdeep Dhillon; Liron Walsh; Bernd Krüger; Stephen C Ward; James H Godbold; Mohamed Radwan; Thomas Schiano; Barbara T Murphy; Bernd Schröppel
Journal:  J Hepatol       Date:  2010-03-30       Impact factor: 25.083

7.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

8.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.

Authors:  G S Hotamisligil; N S Shargill; B M Spiegelman
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

9.  Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon.

Authors:  Seong Gyu Jeon; Hisako Kayama; Yoshiyasu Ueda; Takuya Takahashi; Takashi Asahara; Hirokazu Tsuji; Noriko M Tsuji; Hiroshi Kiyono; Ji Su Ma; Takashi Kusu; Ryu Okumura; Hiromitsu Hara; Hiroki Yoshida; Masahiro Yamamoto; Koji Nomoto; Kiyoshi Takeda
Journal:  PLoS Pathog       Date:  2012-05-31       Impact factor: 6.823

10.  Endotoxemia is associated with an increased risk of incident diabetes.

Authors:  Pirkko J Pussinen; Aki S Havulinna; Markku Lehto; Jouko Sundvall; Veikko Salomaa
Journal:  Diabetes Care       Date:  2011-02       Impact factor: 19.112

View more
  105 in total

1.  Yes-Associated Protein in Kupffer Cells Enhances the Production of Proinflammatory Cytokines and Promotes the Development of Nonalcoholic Steatohepatitis.

Authors:  Kyoungsub Song; Hyunjoo Kwon; Chang Han; Weina Chen; Jinqiang Zhang; Wenbo Ma; Srikanta Dash; Chandrashekhar R Gandhi; Tong Wu
Journal:  Hepatology       Date:  2020-04-11       Impact factor: 17.425

Review 2.  Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective.

Authors:  Jun-Ling Han; Hui-Ling Lin
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

3.  Substrate structure-activity relationship reveals a limited lipopolysaccharide chemotype range for intestinal alkaline phosphatase.

Authors:  Gloria Komazin; Michael Maybin; Ronald W Woodard; Thomas Scior; Dominik Schwudke; Ursula Schombel; Nicolas Gisch; Uwe Mamat; Timothy C Meredith
Journal:  J Biol Chem       Date:  2019-11-08       Impact factor: 5.157

Review 4.  Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease.

Authors:  Veerle Bieghs; Christian Trautwein
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

5.  Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis.

Authors:  Noha F Hassan; Somaia A Nada; Azza Hassan; Mona R El-Ansary; Muhammad Y Al-Shorbagy; Rania M Abdelsalam
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

Review 6.  Pathogenesis of Nonalcoholic Steatohepatitis.

Authors:  Mariana Verdelho Machado; Anna Mae Diehl
Journal:  Gastroenterology       Date:  2016-02-27       Impact factor: 22.682

Review 7.  Application of metagenomics in the human gut microbiome.

Authors:  Wei-Lin Wang; Shao-Yan Xu; Zhi-Gang Ren; Liang Tao; Jian-Wen Jiang; Shu-Sen Zheng
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

8.  Vitamins and non-alcoholic fatty liver disease: A Molecular Insight.

Authors:  Sana Raza; Archana Tewari; Sangam Rajak; Rohit A Sinha
Journal:  Liver Res       Date:  2021-04-04

Review 9.  Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.

Authors:  Junli Ma; Qihang Zhou; Houkai Li
Journal:  Nutrients       Date:  2017-10-16       Impact factor: 5.717

Review 10.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.